Blenrep (belantamab mafodotin) combination receives Breakthrough Therapy Designation in China in R/R multiple myeloma September 24, 2024
FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in 1L AML for Patients Unfit for Induction Chemotherapy Treatment September 24, 2024
IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI September 24, 2024
FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients Announced September 24, 2024
FDA Approves IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC September 24, 2024
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma September 24, 2024
Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With cervical cancer and endometrial carcinoma September 24, 2024
Successful pre-BLA meeting with the US FDA to support BLA for RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024 announced September 17, 2024
FDA Clears IND Application for Ph 1/2 Clinical Trial of an AAV-delivered Cancer Immunotherapy, VNX-101 September 17, 2024
Fast Track Designation Granted for VMT01 for the Diagnosis & Treatment of MC1R-Positive Melanoma September 10, 2024
FDA Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in R/R AML September 10, 2024
FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma September 10, 2024
